NASDAQ:DRMA

Dermata Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy DRMA

*Your capital is at risk

$1.27

-0.0900 (-6.62%)

At Close: Jun 03, 2026

Dermata Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 53.00. In total, the insiders bought 8.5M and sold 86.61K DRMA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	53.00
● Buy	8.5M shares
● Sell	86.61K shares
98% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Jun 01, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 53. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 17, 2026 Buy	Common Stock P-Purchase	Bedoya-toro Munera Maria E SVP, Regulatory Affairs	Officer	1 000 Value: $1K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Fisher Mary Director	Director	2 500 Value: $5K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Bradrick Brittany Director	Director	2 500 Value: $5K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Mento Steven J Director	Director	2 500 Value: $5K
Jan 02, 2026 Buy	Stock Option (right to buy) A-Award	Van Hoose Kyri K. SVP, CFO	C-Suite Officer	18 000 Value: $39.2K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Sandler Andrew Seth Director	Director	2 500 Value: $5K
Jan 02, 2026 Buy	Stock Option (right to buy) A-Award	Nardo Christopher J. Senior Vp, Cdo	Officer	18 000 Value: $39.2K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Scott Kathleen D. Director	Director	2 500 Value: $5K
Jan 02, 2026 Buy	Stock Option (right to buy) A-Award	Bedoya-toro Munera Maria E SVP, Regulatory Affairs	Officer	9 000 Value: $19.6K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Hale David F Director	Director	2 500 Value: $5K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Wierenga Wendell Director	Director	2 500 Value: $5K
Jan 02, 2026 Buy	Stock Option (right to buy) A-Award	Proehl Gerald T President, CEO And Chairman	CEO / President	37 500 Value: $81.8K
Dec 23, 2025 Sell	Warrant (Right to Buy) D-Return	Proehl Gerald T President, Chairman, CEO	CEO / President	78 740 Value: $1,000.0K
Dec 23, 2025 Buy	Warrant (Right to Buy) A-Award	Proehl Gerald T President, Chairman, CEO	CEO / President	78 740 Value: $160.6K
Dec 23, 2025 Buy	Series D Warrant (Right to Buy) A-Award	Proehl Gerald T President, Chairman, CEO	CEO / President	122 549 Value: $250.0K
Dec 23, 2025 Buy	Series C Warrant (Right to Buy) A-Award	Proehl Gerald T President, Chairman, CEO	CEO / President	122 549 Value: $250.0K
Dec 23, 2025 Buy	Common Stock A-Award	Proehl Gerald T President, Chairman, CEO	CEO / President	122 549 Value: $250.0K
Dec 23, 2025 Buy	Common Stock A-Award	Proehl Gerald T President, Chairman, CEO	CEO / President	490 196 Value: $1,000.0K
Dec 23, 2025 Buy	Series D Warrant (Right to Buy) A-Award	Proehl Gerald T President, Chairman, CEO	CEO / President	490 196 Value: $1,000.0K
Dec 23, 2025 Buy	Series C Warrant (Right to Buy) A-Award	Proehl Gerald T President, Chairman, CEO	CEO / President	490 196 Value: $1,000.0K
Dec 23, 2025 Sell	Warrant (Right to Buy) D-Return	Van Hoose Kyri K. SVP, CFO	C-Suite Officer	7 874 Value: $100.0K
Dec 23, 2025 Buy	Warrant (Right to Buy) A-Award	Van Hoose Kyri K. SVP, CFO	C-Suite Officer	7 874 Value: $16.1K
Dec 23, 2025 Buy	Series D Warrant (Right to Buy) A-Award	Van Hoose Kyri K. SVP, CFO	C-Suite Officer	122 549 Value: $250.0K
Dec 23, 2025 Buy	Series C Warrant (Right to Buy) A-Award	Van Hoose Kyri K. SVP, CFO	C-Suite Officer	122 549 Value: $250.0K
Dec 23, 2025 Buy	Common Stock A-Award	Van Hoose Kyri K. SVP, CFO	C-Suite Officer	122 549 Value: $250.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DERMATA THERAPEUTICS, INC.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phas...

Read Full Profile Here